Encube Ethicals announces new high potency topical manufacturing suite
Company's $4 million investment reflects market need for contract service providers who can provide innovative and cost-effective topical manufacturing capabilities for products that include highly potent actives.
Encube Ethicals, an integrated pharmaceutical organisation specialising in topical, transdermal and complex delivery solutions, has announced that its new high potency manufacturing facility for topical formulations is now fully operational.
The new 350-m2 facility, at its site in Goa, follows a $4 million investment by the company last year to bolster its topical manufacturing capabilities. It has an in-house isolator technology that caters for topical products, which include highly potent active pharmaceutical ingredients (HPAPIs), such as pesticides, immunosuppressants and skin oncology drugs.
The facility, which was built in response to customer and market demand for Encube’s services, adds an additional manufacturing line to the company’s portfolio, taking the total number of SKUs manufactured at the site to over 400.
Mehul Shah, managing director at Encube Ethicals, who founded the business in 1998, said: “There is a real gap in the market for contract service providers that can provide innovative and cost-effective topical manufacturing capabilities for products that include highly potent actives.
“As a result, we have experienced high demand for these services and chose to invest in a new facility to increase our capacity. Now that we’re fully operational, we can continue to cater for new small pharma, biotech and virtual customers, as well as continue to support our current multi-national customers who are entering the high potency topical space.”
Based in Mumbai and Goa, the company has over 20 years’ experience of providing an end-to-end, high-quality service for topical products.
The team at the new facility are experienced in handling a number of immunosuppressant topicals including, Tacrolimus and Primecrolimus, as well as skin oncology products such as Fluorouracil. High potency manufacturing is carried out using sophisticated material handling equipment to ensure safety of the operators and the product.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance